Highridge Medical, LLC appears in FDA premarket approval records as the applicant for the Mobi-C® Cervical Disc Prosthesis, filed under two PMA numbers: P110002 for the one-level indication and P110009 for the two-level indication. Both are class 3 intervertebral disc prostheses under product code MJO, reviewed by the Orthopedic advisory committee. The supplied collection holds four linked PMA records: two original approvals and two 30-day notices decided in 2026. [1][3][4]

Documented device and indications

The approved labeling describes Mobi-C® as a cervical disc prosthesis implanted using an anterior approach for reconstruction of the disc from C3-C7 in skeletally mature patients, at one level under P110002 and at two contiguous levels under P110009. The stated conditions include intractable radiculopathy with or without neck pain, or myelopathy, tied to radiographic findings such as herniated nucleus pulposus, spondylosis, or visible loss of disc height. [3][4]

Highridge Medical's own product page describes Mobi-C as an artificial disc designed to maintain neck motion, and states that it was the first cervical disc in the United States approved to treat more than one level of the cervical spine. A company brochure repeats the two-level approval statement and describes a one-step, bone-sparing insertion. [5][8]

Approval history

P110002 for the one-level indication was received on 2011-01-14 and approved on 2013-08-07, with docket number 13M-0987 and a Federal Register notice dated 2013-08-22. P110009 for the two-level indication was received on 2011-03-11 and approved on 2013-08-23, with docket number 13M-1095 and a Federal Register notice dated 2013-09-10. Neither original approval carried an expedited review flag. [3][4]

2026 manufacturing supplements

Both PMA numbers received supplement S040, a 30-Day Notice filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. Each was received on 2026-08-27 and decided OK30 on 2026-09-16. The stated scope covers adding CAM Bioceramics as a raw material supplier of hydroxyapatite powder used in coating the Mobi-C® inferior and superior endplates, and qualifying CeraTek sealing equipment for the final packaging pouch at the same Viant facility. [1][2]

Earlier supplements appear in the broader FDA query results, including S026, a 30-Day Notice received 2020-11-23 and decided 2020-12-15 concerning an additional sealing machine for secondary packaging, and S034, received 2022-11-08 and decided 2022-11-28. These rows are not part of the four-record sample and are not counted in its decision totals. [9]

Applicant identity and record scope

The filings list Highridge Medical, LLC at 10225 Westmoor Dr., Westminister, CO, which is a filing address rather than a verified headquarters. Some records carry the trade name LDR Spine Mobi-C® Cervical Disc Prosthesis, but the public documents do not establish a parent, brand owner, or corporate relationship, so none is asserted here. [1][9]

The supplied collection counts four linked PMA records, with decision counts of two APPR and two OK30; the smaller four-entry sample shows the same split. These are counts of the supplied filings as of the snapshot date, not measures of total portfolio, sales, or safety performance. No recall records were supplied. [1][2][3][4]